The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease

NCT02528617 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No subjects accrued and no potential subjects were identified..

Conditions

Gaucher Disease Type 1
Gaucher Disease Type 3

Interventions

DRUG: Velaglucerase alfa

Sponsor

Baylor Research Institute

Collaborators

[object Object]